ArticleCancer discovery2021
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 94 citations in OpenAlex.
- Article
- A novel combination approach targeting P300 and DNA-PK exploits epigenetic dependencies in acute myeloid leukemia.Molecular therapy. Oncology · 2026Article
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- CARM1-mediated hypoxanthine-enriched exosomes rewire inosine metabolism and impair CD8Cell death and differentiation · 2026Article
- CircIQGAP1-CARM1 axis promotes renal cell carcinoma progression through glycolytic reprogramming.Cell death & disease · 2026Article
- Arginine methylation in cancer: mechanisms and therapeutic implications.Biomarker research · 2025Review
- A STUB1-CHIC2 complex inhibits CD8Nature immunology · 2025Article
- CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer.Cancer research · 2025Article
- Serotonin receptor 5-HTJournal for immunotherapy of cancer · 2025Article
- Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials.Journal for immunotherapy of cancer · 2025Review
- Targeting Regnase-1 unleashes CAR T cell antitumor activity for osteosarcoma and creates a proinflammatory tumor microenvironment.bioRxiv : the preprint server for biology · 2025Article
- Deciphering the role of histone modifications in memory and exhausted CD8 T cells.Scientific reports · 2025Article
- Death-ision: the link between cellular resilience and cancer resistance to treatments.Molecular cancer · 2025Review
- Review
- A narrative review of papillary thyroid carcinoma-related long non-coding RNAs and their relevance to malignant tumors.Translational cancer research · 2025Review
- Crosstalk between metabolism and epigenetics during macrophage polarization.Epigenetics & chromatin · 2025Review
- PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1.Cell death & disease · 2025Article
- Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets.Nature communications · 2025Article
- Super-enhancer DNA methylation in cancer: the mechanism of action and therapeutic directions.Frontiers in oncology · 2025Review
- Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 1 country.
Sushil Kumar *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zexian Zeng *Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Archis Bagati *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Rong En Tay *Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-3647-9271
Lionel A SanzDepartment of Molecular and Cellular Biology and Genome Center, University of California, Davis, California.ORCID 0000-0001-6731-1290
Stella R HartonoDepartment of Molecular and Cellular Biology and Genome Center, University of California, Davis, California.ORCID 0000-0001-6234-3445
Yoshinaga ItoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Fieda AbderazzaqDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Elodie HatchiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-8494-9851
Peng JiangDepartment of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-7828-5486
Adam N R CartwrightDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Olamide OlawoyinDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nathan D MathewsonDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-8895-2609
Jason W PyrdolDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-7726-4192
Mamie Z LiDepartment of Genetics, Harvard Medical School and Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-7188-1330
John G DoenchBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-3707-9889
Matthew A BookerDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael Y TolstorukovDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Stephen J ElledgeDepartment of Genetics, Harvard Medical School and Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, Massachusetts.
Frédéric ChédinDepartment of Molecular and Cellular Biology and Genome Center, University of California, Davis, California.
X Shirley LiuDepartment of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. kai_wucherpfennig@dfci.harvard.edu xsliu@ds.dfci.harvard.edu.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. kai_wucherpfennig@dfci.harvard.edu xsliu@ds.dfci.harvard.edu.ORCID 0000-0002-1829-302X
Harvard University · USDana-Farber Cancer Institute · USUniversity of California, Davis · USHoward Hughes Medical Institute · USBrigham and Women's Hospital · USBroad Institute · USNew Haven Public Schools · US
Funding
Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3MTherapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2MTargeting of a Major Immune Evasion Pathway in Triple-negative Breast CancerR01CA251599 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2020 to 2024
$2.4MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MRegulators of Cancer Immunotherapy ResponseR01CA234018 · NCI · DANA-FARBER CANCER INST · PI BROWN, MYLES A · 2019 to 2022
$2.3MGenomic profiling of pathological R-loop formation in human diseases.R01GM120607 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEDIN, FREDERIC LOUIS · 2016 to 2019
$1.2MNCI NIH HHS P01 CA163222NCI NIH HHS R01 CA234018NCI NIH HHS R01 CA238039NCI NIH HHS R01 CA251599NCI NIH HHS T32 CA207021NIGMS NIH HHS R01 GM120607
Abstract
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited beneficial antitumor activity in both cytotoxic T cells and tumor cells. In T cells,
Indexed as
Cell Line, TumorHumansImmune Checkpoint InhibitorsImmunotherapyNeoplasmsProtein-Arginine N-MethyltransferasesT-Lymphocytescoactivator-associated arginine methyltransferase 1Immune Checkpoint InhibitorsProtein-Arginine N-Methyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.